代谢功能障碍相关脂肪性肝病(MASLD)患者的人体测量指标与死亡风险:一项基于人群的队列研究
该研究基于四个大型队列(NHANES 2017-2020、NHANES III、开滦队列和英国生物银行队列),比较BMI、腰围(WC)及WC相关指标(腰臀比WHR、体型指数BSI、体重调整腰围指数WWI)在MASLD患者中的预后价值。结果显示WC及其相关指标与死亡风险呈显著梯度相关,而BMI无此关联;低BMI伴高WC相关指标者死亡风险最高。作者认为WC相关指标优于BMI,建议MASLD患者常规测量WC。
要点
- WC与肝脏脂肪变性和纤维化的Pearson相关系数优于BMI。
- WC相关指标(WHR、BSI、WWI)最高四分位组较最低组死亡风险显著升高,BMI无显著关联。
- 低BMI伴高WC相关指标者死亡风险最高,BMI相关「肥胖悖论」可能源于指标选择不当。
核心结论
- WC及WC相关指标在预测MASLD预后方面优于BMI;BMI相关的「肥胖悖论」可能是使用错误指标导致的误称;作者建议MASLD患者更常规地测量WC。
研究设计与样本
- 研究人群来自四个大型队列:美国国家健康与营养调查(NHANES 2017-2020和NHANES III)、开滦队列和英国生物银行队列。
- 采用多因素Cox比例风险回归和限制性立方样条评估各人体测量指标与死亡风险的关联。
主要发现
- WC与肝脏脂肪变性和纤维化的Pearson相关系数优于BMI。
- WC最高四分位组 vs 最低四分位组:HR=1.48(95%CI 1.13-1.93)。
- WHR最高四分位组 vs 最低四分位组:HR=3.21(95%CI 2.36-4.37);BSI最高四分位组 vs 最低四分位组:HR=3.22(95%CI 2.48-4.17);WWI最高四分位组 vs 最低四分位组:HR=4.72(95%CI 3.36-6.62)。
- BMI肥胖组 vs 瘦组:HR=0.90(95%CI 0.72-1.12),未达统计学显著。
- 该发现在性别和种族/民族亚组中一致,外部验证支持WC相关指标;MASLD和纤维化患病率随WC相关指标四分位呈剂量依赖性模式;低BMI伴高WC相关指标者死亡风险最高。
临床怎么用
- 作者建议在MASLD患者中更常规地测量WC。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: As the primary anthropometric measure in metabolic dysfunction-associated steatotic liver disease (MASLD), waist circumference (WC) may more accurately reflect the visceral fat distribution than body mass index (BMI). This study aimed to compare the prognostic value of BMI, WC and WC-related indices including waist-hip ratio (WHR), body shape index (BSI) and weight-adjusted-waist index (WWI) in individuals with MASLD. METHODS: The study population was derived from four large-scale cohorts: the National Health and Nutrition Examination Survey (NHANES 2017-2020 and NHANES III), the Kailuan Cohort and the UK Biobank Cohort. We evaluated the mortality risk across these measures using multivariate Cox proportional hazards regression and restrictive cubic spline. RESULTS: The Pearson correlation coefficient of WC with hepatic steatosis and fibrosis was better than that of BMI. WC [Quartile 4 vs. Quartile 1: HR (hazard ratio) = 1.48 (95% confidence interval (CI) 1.13-1.93)] and WC-related indices [Quartile 4 vs. Quartile 1: WHR HR = 3.21 (95% CI 2.36-4.37); BSI HR = 3.22 (95% CI 2.48-4.17); WWI HR = 4.72 (95% CI 3.36-6.62)], but not BMI [obesity vs. lean: HR = 0.90 (95% CI 0.72-1.12)], indicated a significant mortality risk gradient among individuals with MASLD. The finding was consistent across sex and racial/ethnic subgroups, with external validation supporting the WC-related indices. MASLD and fibrosis prevalence showed a dose-dependent pattern across WC-related index quartiles. Notably, low BMI and high WC-related indices portended the highest mortality risk. CONCLUSIONS: WC and WC-related indices are better parameters in prognosticating MASLD than BMI. The BMI-related 'obesity paradox' may be a misnomer resulting from the use of an incorrect metric. WC should be measured more routinely among individuals with MASLD.
引用
- Yeo YH, Zhu Y, Gao J, et al. Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Population-Based Cohort Study. Aliment Pharmacol Ther. 2025. PMID: 40366297. doi:10.1111/apt.70174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。